PMID- 31924632
OWN - NLM
STAT- MEDLINE
DCOM- 20210210
LR  - 20210210
IS  - 2044-6055 (Electronic)
IS  - 2044-6055 (Linking)
VI  - 10
IP  - 1
DP  - 2020 Jan 9
TI  - Postoperative intravenous parecoxib sodium followed by oral celecoxib post total 
      knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, 
      double-blind, randomised, placebo-controlled trial.
PG  - e030501
LID - 10.1136/bmjopen-2019-030501 [doi]
LID - e030501
AB  - OBJECTIVES: To evaluate the morphine-sparing effects of the sequential treatment 
      versus placebo in subjects undergoing total knee arthroplasty (TKA), the effects 
      on pain relief, inflammation control and functional rehabilitation after TKA and 
      safety. DESIGN: Double-blind, pragmatic, randomised, placebo-controlled trial. 
      SETTING: Four tertiary hospitals in China. PARTICIPANTS: 246 consecutive patients 
      who underwent elective unilateral TKA because of osteoarthritis (OA). 
      INTERVENTIONS: Patients were randomised 1:1 to the parecoxib/celecoxib group or 
      the control group. The patients in the parecoxib/celecoxib group were supplied 
      sequential treatment with intravenous parecoxib 40 mg (every 12 hours) for the 
      first 3 days after surgery, followed by oral celecoxib 200 mg (every 12 hours) 
      for up to 6 weeks. The patients in the control group were supplied with the 
      corresponding placebo under the same instructions. PRIMARY AND SECONDARY OUTCOME 
      MEASURES: The primary endpoint was the cumulative opioid consumption at 2 weeks 
      post operation (intention-to-treat analysis). Secondary endpoints included the 
      Knee Society Score, patient-reported outcomes and the cumulative opioid 
      consumption. RESULTS: The cumulative opioid consumption at 2 weeks was 
      significantly smaller in the parecoxib/celecoxib group than in the control group 
      (median difference, 57.31 (95% CI 34.66 to 110.33)). The parecoxib/celecoxib 
      group achieving superior Knee Society Scores and EQ-5D scores and greater Visual 
      Analogue Scale score reduction during 6 weeks. Interleukin 6, erythrocyte 
      sedation rate and C-reactive protein levels were reduced at 72 hours, 2 weeks and 
      4 weeks and prostaglandin E2 levels were reduced at 48 hours and 72 hours in the 
      parecoxib/celecoxib group compared with the placebo group. The occurrence of 
      adverse events (AEs) was significantly lower in the parecoxib/celecoxib group. 
      CONCLUSIONS: The sequential intravenous parecoxib followed by oral celecoxib 
      regimen reduces morphine consumption, achieves better pain control and functional 
      recovery and leads to less AEs than placebo after TKA for OA. TRIAL REGISTRATION 
      NUMBER: ClinicalTrials.gov (ID: NCT02198924).
CI  - (c) Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No 
      commercial re-use. See rights and permissions. Published by BMJ.
FAU - Zhuang, Qianyu
AU  - Zhuang Q
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Tao, Liyuan
AU  - Tao L
AD  - Research Center of Clinical Epidemiology, Peking University 3rd Hospital, 
      Beijing, China.
FAU - Lin, Jin
AU  - Lin J
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Jin, Jin
AU  - Jin J
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Qian, Wenwei
AU  - Qian W
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Bian, Yanyan
AU  - Bian Y
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Li, Yulong
AU  - Li Y
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Dong, Yulei
AU  - Dong Y
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Peng, Huiming
AU  - Peng H
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Li, Ye
AU  - Li Y
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Fan, Yu
AU  - Fan Y
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Feng, Bin
AU  - Feng B
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Gao, Na
AU  - Gao N
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Sun, Tiezheng
AU  - Sun T
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Lin, Jianhao
AU  - Lin J
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China.
FAU - Zhang, Miaofeng
AU  - Zhang M
AD  - Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University, 
      Zhejiang, China.
FAU - Yan, Shigui
AU  - Yan S
AD  - Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University, 
      Zhejiang, China.
FAU - Shen, Bin
AU  - Shen B
AD  - Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Pei, Fuxing
AU  - Pei F
AD  - Department of Orthopedics, West China Hospital, Sichuan University, Chengdu, 
      China.
FAU - Weng, Xisheng
AU  - Weng X
AUID- ORCID: 0000-0003-0083-5190
AD  - Department of Orthopedics, Peking Union Medical College Hospital, Beijing, China 
      wengxishengpumch@126.com.
LA  - eng
SI  - ClinicalTrials.gov/NCT02198924
PT  - Journal Article
PT  - Multicenter Study
PT  - Pragmatic Clinical Trial
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20200109
PL  - England
TA  - BMJ Open
JT  - BMJ open
JID - 101552874
RN  - 0 (Cyclooxygenase 2 Inhibitors)
RN  - 0 (Isoxazoles)
RN  - 9TUW81Y3CE (parecoxib)
RN  - JCX84Q7J1L (Celecoxib)
SB  - IM
EIN - BMJ Open. 2020 Mar 9;10(3):e030501corr1. PMID: 32152176
MH  - Administration, Intravenous
MH  - Administration, Oral
MH  - Aged
MH  - Arthroplasty, Replacement, Knee/*adverse effects
MH  - Celecoxib/*administration & dosage
MH  - Cyclooxygenase 2 Inhibitors/administration & dosage
MH  - Double-Blind Method
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Isoxazoles/*administration & dosage
MH  - Male
MH  - Osteoarthritis, Knee/*surgery
MH  - Pain, Postoperative/*drug therapy
MH  - Postoperative Care/*methods
MH  - Retrospective Studies
MH  - Treatment Outcome
PMC - PMC6955469
OTO - NOTNLM
OT  - celecoxib
OT  - cumulative opioid consumption
OT  - opioid sparing
OT  - parecoxib
OT  - postoperative pain
OT  - total knee arthroplasty
COIS- Competing interests: None declared.
EDAT- 2020/01/12 06:00
MHDA- 2021/02/11 06:00
PMCR- 2020/01/09
CRDT- 2020/01/12 06:00
PHST- 2020/01/12 06:00 [entrez]
PHST- 2020/01/12 06:00 [pubmed]
PHST- 2021/02/11 06:00 [medline]
PHST- 2020/01/09 00:00 [pmc-release]
AID - bmjopen-2019-030501 [pii]
AID - 10.1136/bmjopen-2019-030501 [doi]
PST - epublish
SO  - BMJ Open. 2020 Jan 9;10(1):e030501. doi: 10.1136/bmjopen-2019-030501.